Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis

Digestive and Liver Disease

Volumn 47, Issue 4, 2015, Pages 324-330

  Mancuso, Andrea ^a,b   Mazzola, Alessandra ^c   Cabibbo, Giuseppe ^c   Perricone, Giovanni ^a   Enea, Marco ^d   Galvano, Antonio ^d   Zavaglia, Claudio ^a   Belli, Luca ^a   Cammà, Calogero ^c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Internal Medicine Department   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF PALERMO   (Italy)

Author keywords

Hepatocellular carcinoma; Liver transplant; Recurrence; Sorafenib

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; VASCULOTROPIN RECEPTOR;

ARTICLE; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DRUG SAFETY; GASTROINTESTINAL DISEASE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLISHING; SEX DIFFERENCE; SKIN DISEASE; SURVIVAL RATE; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; ETIOLOGY; LIVER NEOPLASMS; MORTALITY; POSTOPERATIVE PERIOD; TRENDS; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; POSTOPERATIVE PERIOD; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84925293050     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2015.01.001     Document Type: Article

References (50)

1. Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1222.
2. Kudo M., Izumi N., Kokudo N., et al. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology 2010 Updated Version. Digestive Diseases 2011, 29:339-364.
3. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012, 56:908-943.
4. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine 1996, 334:693-699.
5. Mela M., Mancuso A., Burroughs A.K. Review article: hepatocellular carcinoma: indications for liver transplantations. Alimentary Pharmacology and Therapeutics 2003, 17(S2):130-137.
6. Clavien P.A., Lesurtel M., Bossuyt P.M., et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncology 2012, 13:e11-e22.
7. Yao F.Y., Xiao L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. American Journal of Transplantation 2007, 7:2587-2596.
8. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncology 2009, 10:35-43.
9. Raj A., McCall J., Gane E. Validation of the "Metroticket" predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma. Journal of Hepatology 2011, 55:1063-1068.
10. Schwartz M., Dvorchik I., Roayaie S., et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. Journal of Hepatology 2008, 49:581-588.
11. Yao F.Y., Kerlan R.K., Hirose R., et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008, 48:819-827.
12. Ravaioli M., Grazi G.L., Piscaglia F., et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. American Journal of Transplantation 2008, 8:2547-2557.
13. De Carlis L., Di Sandro S., Giacomoni A., et al. Beyond the Milan Criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation. Journal of Clinical Gastroenterology 2012, 46:78-86.
14. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008, 359:378-390.
15. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncology 2009, 10:25-34.
16. Dharancy S., Romano O., Lorho R., et al. Tolerability and efficacy of sorafenib in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. Hepatology 2008, 48:310A.
17. Feun L.G., Levi D., Moon J., et al. Sorafenib in hepatocellular carcinoma patients after liver transplantation. Journal of Clinical Oncology 2009, 29:15.
18. Kim R., El-Gazzaz G., Tan A., et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010, 79:62-66. 10.1159/000319548.
19. Tan W.F., Qiu Z.Q., Yu Y., et al. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacologica Sinica 2010, 31:1643-1648.
20. Valdivieso A., Bustamante J., Gastaca M., et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplantation Proceedings 2010, 42:660-662.
21. Yoon D.H., Ryoo B.Y., Ryu M.H., et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Journal of Clinical Oncology 2010, 40:768-773.
22. Pfiffer T.E., Seehofer D., Nicolaou A., et al. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era. Tumori 2011, 97:436-441.
23. Gomez-Martin C., Bustamante J., Castroagudin J.F., et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transplantation 2012, 18:45-52.
24. Sotiropoulos G.C., Nowak K.W., Fouzas I., et al. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. Transplantation Proceedings 2012, 44:2754-2756.
25. Staufer K., Fischer L., Seegers B., et al. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Transplant International 2012, 25:1158-1164.
26. Vitale A., Boccagni P., Kertusha X., et al. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Transplantation Proceedings 2012, 44:1989-1991.
27. Weinmann A., Niederle I.M., Koch S., et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Digestive and Liver Disease 2012, 44:432-437.
28. Pfeiffenberger J., Koschny R., Hoffmann K., et al. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. Langenbeck's Archives of Surgery 2013, 398:1123-1128.
29. Sposito C., Mariani L., Germini A., et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. Journal of Hepatology 2013, 59:59-66.
30. Waghray A., Balci B., El-Gazzaz G., et al. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clinical Transplantation 2013, 27:555-561.
31. Zavaglia C., Airoldi A., Mancuso A., et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature. European Journal of Gastroenterology and Hepatology 2013, 25:180-186.
32. De Simone P., Crocetti L., Pezzati D., et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplantation Proceedings 2014, 46:241-244.
33. Mancuso A., Mazzarelli C., Perricone G., et al. Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue. Journal of Hepatology 2014, 3:261.
34. Wells GA, Shea B, O'Connell D, et al. Home>Our Research>Research Programs>Clinical Epidemiology>The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses [Web page]. Ottawa, ON: Ottawa Hospital Research Institute; n.d. Available online at: [accessed 10.02.12]. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
35. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982, 5:649-655.
36. Iavarone M., Cabibbo G., Piscaglia F., et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011, 54:2055-2063.
37. Cabibbo G., Enea M., Attanasio M., et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010, 51:1274-1283.
38. Combescure C., Foucherb Y., Jackson D. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Statistics in Medicine 2014, 33:2521-2537.
39. Forman L.M., Lewis J.D., Berlin J.A., et al. The association between hepatitis C infection and serviva after orthotopic liver transplantation. Gastroenterology 2002, 112:889-896.
40. Belli L.S., Burroughs A.K., Burra P., et al. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study. Liver Transplantation 2007, 13:733-740.
41. Shah D.R., Shah R.R., Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Safety 2013, 36:413-426.
42. Mancuso A., Zavaglia C., Bai F., et al. Sorafenib hepatotoxicity seems to be enhanced by HAARTS interaction during treatment of advanced hepatocelluler carcinoma in HIV-infected patients. Alimentary Pharmacology and Therapeutics 2013, 38:1414-1416.
43. Reig M., Torres F., Rodriguez-Lope C., et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. Journal of Hepatology 2014, 61:318-324.
44. Mancuso A., Airoldi A., Vigano R., et al. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. Digestive and Liver Disease 2011, 43:754.
45. Bhoori S., Toffanin S., Sposito C., et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. Journal of Hepatology 2010, 52:771-775.
46. Toso C., Merani S., Bigam D.L., et al. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010, 51:1237-1243.
47. Cammà C., Cabibbo G., Petta S., et al. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology 2013, 57:1046-1054.
48. Abu-Alfa G.K. Sorafenib use in hepatocellular carcinoma: more questions than answers. Hepatology 2014, 60:15-18.
49. Cabibbo G., Maida M., Cammà C., et al. Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?. Expert Review of Anticancer Therapy 2013, 13:1355-1361.
50. Sacco R., Gadaleta-Caldarola G., Galati G., et al. European Association for the Study of the Liver Hepatocellular Carcinoma summit 2014: old questions, new (or few) answers?. Future Oncology 2014, 10:1719-1721.